Type 2 diabetics face a flood of wrong information (again)

Part of my current T2D treatment

Two weeks ago, the New York Times published an article penned by Elisabeth Rosenthal about Type 2 diabetes and its treatment. The article covered how Type 2 diabetics, seen as the new cash cow by the pharmaceutical industry, are being overwhelmed by costly drugs and tests. With the rising number of Type 2 diabetics, the cost of treatment is indeed a timely topic. But the article is also riddled with errors and misconceptions about Type 2 diabetes. More importantly, it places more emphasis on the cost rather than those suffering from the condition.